Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell-cycle dysregulation and anticancer therapy.

Zoe A Stewart1, Matthew D Westfall, Jennifer A Pietenpol

  • 1Department of Biochemistry, Center in Molecular Toxicology and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Trends in Pharmacological Sciences
|March 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Lean, Obese, and Weight-Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T-cell Populations.

Cancer research·2025
Same author

Highly multiplexed imaging reveals prognostic immune and stromal spatial biomarkers in breast cancer.

JCI insight·2025
Same author

Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations.

bioRxiv : the preprint server for biology·2024
Same author

Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.

Cancer research communications·2024
Same author

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.

JAMA oncology·2023
Same author

Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2023
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026
Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026
Same journal

Which HTT transcript to lower?

Trends in pharmacological sciences·2026
See all related articles

Cell-cycle checkpoints prevent genomic instability in normal cells but are often dysregulated in cancer. Targeting these checkpoints offers new strategies for cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • Cell-cycle dysregulation is a key characteristic of cancer cells.
  • Cell-cycle arrest following DNA damage is vital for maintaining genomic integrity.
  • Checkpoint pathways regulate the cell cycle in response to stressors.

Purpose of the Study:

  • To provide an overview of cell-cycle regulation mechanisms.
  • To discuss current anticancer therapies targeting checkpoint signaling.
  • To explore strategies for developing novel chemotherapeutic agents.

Main Methods:

  • Literature review of cell-cycle regulation.
  • Analysis of current checkpoint-targeting anticancer therapies.
  • Exploration of future therapeutic strategies.

Related Experiment Videos

Main Results:

  • Cell-cycle checkpoints are essential for preventing genetic alterations.
  • Defective checkpoints contribute to cancer development (tumorigenesis).
  • Checkpoint abrogation impacts cancer cell sensitivity to chemotherapy.

Conclusions:

  • Understanding cell-cycle regulation is crucial for cancer treatment.
  • Targeting checkpoint signaling pathways presents therapeutic opportunities.
  • Novel chemotherapeutic agents can be developed by targeting these pathways.